Anticancer Drugs. 1990 Oct;1(1):5-13.

Mitomycin C: mechanism of action, usefulness and limitations.

Source

Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek, The Netherlands.

Abstract

The mitomycins are antitumor antibiotics that are under investigation now for more than 30 years. Mitomycin C (MMC) is the best investigated subtype. It serves as a prototype for drugs with bioreductive alkylation, which is a unique feature of this class. MMC is mainly active under anaerobic circumstances. The pharmacokinetics are linear in a two-compartment model. The main toxicities of MMC are thrombocytopenia and leucocytopenia. Rare but severe side effects are a hemolytic uremic syndrome, pneumonitis and cardiac failure. MMC has a wide clinical antitumor spectrum with efficacy in various tumor types such as gastric cancer, pancreatic cancer, breast cancer, non-small cell lung cancer, cervical cancer, prostate cancer and bladder cancer. Still, the above mentioned side effects prevent a more widespread use. The most important features of the drug will be reviewed.

PMID:: 2131038; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Mitomycin

LinkOut - more resources

Full Text Sources

Ovid Technologies, Inc.

Molecular Biology Databases

MITOMYCIN C - HSDB

Supplemental Content

Save items

Related citations in PubMed

Mitomycin C-related hemolytic uremic syndrome in cancer patients. [Anticancer Drugs. 1998]
Mitomycin C-related hemolytic uremic syndrome in cancer patients.
Schiebe ME, Hoffmann W, Belka C, Bamberg M. Anticancer Drugs. 1998 Jun; 9(5):433-5.
Review [Recent advanced studies on mitomycins, antitumor activity and mode of action]. [Gan To Kagaku Ryoho. 1987]
Review [Recent advanced studies on mitomycins, antitumor activity and mode of action].
Taguchi T, Morimoto M. Gan To Kagaku Ryoho. 1987 Jul; 14(7):2396-409.
Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia. [J Cancer Res Clin Oncol. 1996]
Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T, Kasahara K, Shibata K, Numata Y, Heki U, Shirasaki H, Iwasa K, Fujimura M, Matsuda T. J Cancer Res Clin Oncol. 1996; 122(1):21-6.
Review Mitomycin C: a clinical update. [Cancer Treat Rev. 2001]
Review Mitomycin C: a clinical update.
Bradner WT. Cancer Treat Rev. 2001 Feb; 27(1):35-50.
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. [Clin Cancer Res. 1997]
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D. Clin Cancer Res. 1997 Sep; 3(9):1467-72.

See reviews... See all...

Cited by 7 PubMed Central articles

Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model. [Nucleic Acids Res. 2010]
Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model.
Weng MW, Zheng Y, Jasti VP, Champeil E, Tomasz M, Wang Y, Basu AK, Tang MS. Nucleic Acids Res. 2010 Nov; 38(20):6976-84. Epub 2010 Jul 6.
Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs. [J Biol Chem. 2010]
Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs.
Snodgrass RG, Collier AC, Coon AE, Pritsos CA. J Biol Chem. 2010 Jun 18; 285(25):19068-75. Epub 2010 Apr 23.
Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. [ACS Chem Biol. 2007]
Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways.
Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M, Bargonetti J. ACS Chem Biol. 2007 Jun 15; 2(6):399-407. Epub 2007 May 25.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Mitomycin C: mechanism of action, usefulness and limitations.
Mitomycin C: mechanism of action, usefulness and limitations.
Anticancer Drugs. 1990 Oct ;1(1):5-13.

PubMed
Tear osmolarity in the diagnosis and management of dry eye disease.
Tear osmolarity in the diagnosis and management of dry eye disease.
Am J Ophthalmol. 2011 May ;151(5):792-798.e1. Epub 2011 Feb 18 .

PubMed
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood...
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting.
Am J Obstet Gynecol. 2011 Mar ;204(3):205.e1-11. Epub 2011 Feb 18 .

PubMed
Cardiac resynchronization therapy is more effective in women than in men: the MA...
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial.
J Am Coll Cardiol. 2011 Feb 15 ;57(7):813-20.

PubMed
The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment ...
The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.
J Am Coll Cardiol. 2011 Feb 15 ;57(7):784-91.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: